These results show that first, CSPG4-targeting CAR-Ms inhibit melanoma growth in vivo, and second, tumor growth inhibition occurs in the absence of adaptive immune cells, suggesting the innate immune system is sufficient for this response. The gene discussed is MTR; the disease is neoplasm.